VXRT - Could Investing in Vaxart Make You a Millionaire?
For investors seeking to turn a modest initial investment into millions, explosive growth is desirable. And unexpectedly explosive growth is exactly why many healthcare investors are now looking at the vaccine start-up Vaxart (NASDAQ: VXRT) with newfound appreciation.
Vaxart's stock soared more than 90% last week when it announced that its COVID-19 vaccine candidate had been chosen to participate in the U.S. government's accelerated vaccine development program, and that it planned to scale up its vaccine manufacturing capabilities to supply its anticipated clinical-trial needs. Before these two announcements, the company was barely on the market's radar, in part because it only joined the Russell 3000 index this week.
Given the company's new-kid-on-the-block status and highly risky industry, investors will need to carefully consider whether buying Vaxart is a sound path to earning millions.